First-in-disease use of kyverna therapeutics' kyv-101 in patient with severe stiff-person syndrome published in proceedings of the national academy of sciences (pnas)

Patient received kyv-101, a fully human anti-cd19 car t-cell product candidate, as part of a named-patient treatment option after failure to respond to conventional therapies significant improvement in walking distance and 40% reduction in gabaergic medications were among the reported results well-tolerated treatment with low-grade crs and no icans supports continued exploration of kyv-101 in neuroimmunological disease emeryville, calif. , june 17, 2024 /prnewswire/ -- kyverna therapeutics, inc. (kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today the publication in proceedings of the national academy of sciences (pnas)1 of a report describing the first use of kyv-101, a fully human anti-cd19 chimeric antigen receptor (car) t-cell product candidate, in a 69-year-old patient suffering from treatment-refractory stiff-person syndrome (sps) as part of a named-patient use in germany for critically ill individuals who fail conventional therapies.
KYTX Ratings Summary
KYTX Quant Ranking